{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"TC BioPharm (Holdings) plc"},"Symbol":{"label":"Symbol","value":"TCBP"},"Address":{"label":"Address","value":"MAXIM 1, 2 PARKLANDS WAY,HOLYTOWN, MOTHERWELL, SCOTLAND, ML1 4WR, United Kingdom"},"Phone":{"label":"Phone","value":"+44 1414337557"},"Industry":{"label":"Industry","value":"Biotechnology: Biological Products (No Diagnostic Substances)"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"Europe"},"CompanyDescription":{"label":"Company Description","value":"TC BioPharm (Holdings) PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapy products that are based on its proprietary allogeneic gamma delta T (abbreviated as GD-T) cell platform."},"CompanyUrl":{"label":"Company Url","value":"https://www.tcbiopharm.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Bryan Kobel","title":"Chief Executive Officer & Director"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}